Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0

NCT07682415 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

CLL / SLL

Interventions

DRUG: 12 cycles of zanubrutinib followed by 12 cycles of zanubrutinib in combination with sonrotoclax
DRUG: zanubrutinib maintenance until disease progression

Sponsor

Yi Shuhua

Collaborators

[object Object]